IceCure Medical has issued bonds worth US$5.7 million
IceCure Medical Ltd. has completed a fundraising to refinance and develop the company.
IceCure is an Israeli medical device company that has developed technology to eliminate benign and cancerous tumors in the breast and other parts of the body by freezing the tumor during treatment in a clinic and without surgery, using the ProSense system developed at the Elisha Private Hospital in Haifa.
Oaklins’ team in Israel advised IceCure Medical Ltd. and acted as the leader of the distributors’ consortium.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more